Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway.
Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway.
复制标题
丹芪丸通过FATP-CPTI通路调节心肌缺血所致脂代谢紊乱
DOI：
10.1186/s12906-015-0548-0
复制
发表时间：
2015-02-21
影响因子：
--
通讯作者：
Wang W
中科院分区：
文献类型：
--
作者：
Wang Y;Li C;Wang Q;Shi T;Wang J;Chen H;Wu Y;Han J;Guo S;Wang Y;Wang W
丹芪丸（DQP）是由丹参、三七等中药组成，在我国被广泛应用于治疗心肌缺血。其对心肌梗死相关脂质代谢紊乱的调节作用尚未得到全面的研究。本研究旨在系统研究DQP对心肌缺血所致脂质代谢紊乱的调节机制。结扎冠状动脉左前降支建立心肌缺血大鼠模型。模型组给予生理盐水，实验组给予丹芪水溶液（1.5 mg/kg），阳性对照组给予普伐他汀水溶液（1.2 mg/kg）。另设假手术组作为阴性对照。治疗后28 d，检测各组大鼠心功能和脂代谢紊乱程度。心肌缺血可引起血脂紊乱，表现为甘油三酯（TG）、低密度脂蛋白（LDL）、载脂蛋白B（Apo-B）和3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）的升高。DQP可降低TG、LDL、Apo-B和HMGCR水平。模型组脂质转运通路、脂肪酸转运蛋白（FATP）和肉毒碱棕榈酰转移酶I（CPTI）表达下调。DQP可通过上调该脂质转运途径改善血脂代谢。调节脂质代谢的转录因子过氧化物酶体增殖物激活受体α（PPARα）和维甲酸X受体（RXRs）也被DQP上调。此外，DQP能够改善心功能，并通过增加心脏舒张容积上调射血分数（EF）。DQP是治疗心肌缺血所致血脂异常的理想替代药物。
Danqi Pill (DQP), which contains Chinese herbs Salvia miltiorrhiza Bunge and Panax notoginseng, is widely used in the treatment of myocardial ischemia (MI) in China. Its regulatory effects on MI-associated lipid metabolism disorders haven’t been comprehensively studied so far. We aimed to systematically investigate the regulatory mechanism of DQP on myocardial ischemia-induced lipid metabolism disorders. Myocardial ischemia rat model was induced by left anterior descending coronary artery ligation. The rat models were divided into three groups: model group with administration of normal saline, study group with administration of DanQi aqueous solution (1.5 mg/kg) and positive-control group with administration of pravastatin aqueous solution (1.2 mg/kg). In addition, another sham-operated group was set as negative control. At 28 days after treatment, cardiac function and degree of lipid metabolism disorders in rats of different groups were measured. Plasma lipid disorders were induced by myocardial ischemia, with manifestation of up-regulation of triglyceride (TG), low density lipoprotein (LDL), Apolipoprotein B (Apo-B) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). DQP could down-regulate the levels of TG, LDL, Apo-B and HMGCR. The Lipid transport pathway, fatty acids transport protein (FATP) and Carnitine palmitoyltransferase I (CPTI) were down-regulated in model group. DQP could improve plasma lipid metabolism by up-regulating this lipid transport pathway. The transcription factors peroxisome proliferator-activated receptor α (PPARα) and retinoid X receptors (RXRs), which regulate lipid metabolism, were also up-regulated by DQP. Furthermore, DQP was able to improve heart function and up-regulate ejection fraction (EF) by increasing the cardiac diastolic volume. Our study reveals that DQP would be an ideal alternative drug for the treatment of dyslipidemia which is induced by myocardial ischemia.
登录
查看更多内容
影响因子：
120.7
作者：
Erqou, Sebhat;Kaptoge, Stephen;Perry, Philip L.;Di Angelantonio, Emanuele;Thompson, Alexander;White, Ian R.;Marcovina, Santica M.;Collins, Rory;Thompson, Simon G.;Danesh, John
通讯作者：
Danesh, John
DOI：
10.1196/annals.1320.002
发表时间：
2004-01-01
期刊：
CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT
影响因子：
--
作者：
Jogl, G;Hsiao, YS;Tong, L
通讯作者：
Tong, L
影响因子：
2.9
作者：
Hardwick JP;Osei-Hyiaman D;Wiland H;Abdelmegeed MA;Song BJ
通讯作者：
Song BJ
影响因子：
5.4
作者：
Fan, Ji-Shan;Liu, Dan-Ning;He, Feng-Tian
通讯作者：
He, Feng-Tian
影响因子：
3.5
作者：
ISSEMANN, I;PRINCE, RA;GREEN, S
通讯作者：
GREEN, S